Article Open Access in Pharmacological Reports 1/2020

We strongly recommend reading an interesting article titled "New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis" published in Open Access (Pharmacological Reports 1/2020):

https://link.springer.com/article/10.1007/s43440-019-00020-1

Authors: Natalia Pydyn, Katarzyna Miękus, Jolanta Jura and Jerzy Kotlinowski described how the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Globally, it is currently the most common liver disease and is estimated to affect up to 25% of the population. In the first stage, NAFLD is characterized by simple hepatic steatosis (NAFL, nonalcoholic fatty liver) that might progress to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis or hepatocellular carcinoma.

In this review, authors discuss the global burden of NAFLD, together with future perspectives on how this epidemic could be restrained. There is also an urgent need for the development of new medical strategies for NAFLD patients. We aim to present the beneficial effects of life-style modifications that should be advised to both non-obese and obese NAFLD patients.